NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001181

Registered date:10/06/2008

Salvage chemotherapy followed by autoSCT for relapsed HIV associated lymphoma

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedRelapsed or refractory HIV associated lymphoma
Date of first enrollment2008/06/01
Target sample size20
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Salvage regimen; etoposide60mg/m2 div for 2hrs day1-4 mPSL500mg div for 30min day1-5 carboplatin100mg/m2 cont.div day1-4 AraC2g/m2 div for 3hrs day5 Rituximab375mg div day1 for a case with CD20 positive 1course=21days, 1-4courses Peripheral blood stem cells should be collected after 1-4 course using G-CSF Patients who achieved PR or CR after 1-4courses of salvage regimen, should be treated with MEAM regimen followed by autologous peripheral blood stem cell transplantation. More than 2x10E6/kg of CD34-posiive cells should be infused on day0. MEAM regimen; MCNU300mg/m2 div for 1hr day-6 etoposide200mg/m2 div for 3hrs day-5~-3 AraC200mg/m2 div for 3 hrs day-5~-3 L-PAM140mg/m2 bolus iv day-2

Outcome(s)

Primary Outcome2year over all survival
Secondary Outcomesurvival at 100 days after transplantation, CR rate, therapy related toxicity, the number of collected stem cells, the rate of engraftment, the number of CD4 positive cells, the quantity of HIV-virus

Key inclusion & exclusion criteria

Age minimum15years-old
Age maximum60years-old
GenderMale and Female
Include criteria
Exclude criteriaExclusion criteria for salvage regimen 1)Organ dysfunction a)EF<40% by cardiac sonography b)PaO2<50mmHg or SaO2<90% c)serumCr>3.0mg/dl d)Total-bilirubin>3.0mg/dl or ALT>five times upper limit of the institutional normal value 2)Serious active infection Exclusion criteria for PBSCT 1)Organ dysfunction a)EF<50% by cardiac sonography b)PaO2<60mmHg c)serumCr>2.0mg/dl d)Total-bilirubin>2.0mg/dl or ALT>twice of upper limit of the institutional normal value 2)Uncontrollable HIV virus load and resistant to HAART 3)Uncontrollable diabetes which is resistant to insulin 4)Uncontrollable hypertension 5)Intractable and active infection 6)Intractable invasion of lymphoma to CNS 7)Pregnant or possible pregnant women or breast feeding

Related Information

Contact

public contact
Name Shotaro Hagiwara
Address Japan
Telephone
E-mail shagiwar@imcj.hosp.go.jp
Affiliation International Medical Center of JAPAN Division of Hematology
scientific contact
Name Shotaro Hagiwara
Address 1-21-1Toyama, Shinjuku, Tokyo Japan
Telephone 03-3202-7181
E-mail
Affiliation International Medical Center of JAPAN Division of Hematology